Ryan Kors
Vice President of Investor Relations
Replay available
Johnson & Johnson (NYSE: JNJ) Q2 2026 earnings conference call, held 2026-07-15. Replay captured from the company's public earnings webcast.

Vice President of Investor Relations
Chairman and Chief Executive Officer
Executive Vice President and Chief Financial Officer
Executive Vice President, Worldwide Chairman of Innovative Medicine
Executive Vice President, Innovative Medicine Research and Development
Executive Vice President, Worldwide Chairman of MedTech
Analyst, J.P. Morgan
Analyst, Goldman Sachs
Analyst, Wells Fargo
Analyst, Morgan Stanley
Analyst, Citibank
Analyst, Guggenheim Securities
Analyst, Wolf Research
Analyst, Raymond James
Analyst, TD Cal
Good morning and welcome to Johnson & Johnson's second quarter 2026 earnings conference call. All participants will be in a listen-only mode until the question and answer session of the conference. This call is being recorded. If anyone has any objections, you may disconnect at this time. If you experience technical difficulties during the conference, you may press star zero to reach the operator. I will now turn the conference call over to Johnson & Johnson. You may begin. Hello everyone, this is Ryan Kors, Vice President of Investor Relations for Johnson & Johnson. I'm excited to be here today and to lead the Investor Relations team moving forward. Welcome to our company's review of business results for the second quarter of 2026 and our financial outlook for the full year. First, a few logistics. As a reminder, today's presentation and associated schedules are available on the Investor Relations section of the Johnson & Johnson website at investor.jnj.com. Please note that this presentation contains forward-looking statements regarding, among other things, the company's future operating and financial performance, market position, and business strategy. You are cautioned not to rely on these forward-looking statements, which are based on the current expectations of future events using the information available as of the date of this recording. They are subject to certain risks and uncertainties that may cause the company's actual results to differ materially from those projected. The description of these risks, uncertainties, and other factors can be found in our SEC filings, including our 2025 Form 10-K, which is available at investor.jnj.com and on the SEC's website. Additionally, several of the products and compounds discussed today are being developed in collab...